The required number of days of written notice to cancel the license agreement.

No definition available.

Name:	akus_AdvanceWrittenNoticeToCancelLicenseAgreementPeriod
Namespace Prefix:	akus_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The period of time after completion of specified toxicology studies for a licensed product during which the entity must file the new drug application.

+ References

No definition available.

+ Details

Name:	akus_LicenseAgreementPeriodForFilingNewDrugApplication
Namespace Prefix:	akus_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of milestone payment amount.

+ References

No definition available.

+ Details

Name:	akus_MilestonePaymentAmount
Namespace Prefix:	akus_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Represents the number of domestic patients.

+ References

No definition available.

+ Details

Name:	akus_NumberOfDomesticPatients
Namespace Prefix:	akus_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

The period for start first commercial sale of product.

+ References

No definition available.

+ Details

Name:	akus_PeriodForStartCommercialSaleOfProduct
Namespace Prefix:	akus_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The fair value of stock issued in noncash financing activities.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586

+ Details

Name:	us-gaap_StockIssued1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=akus_MeeLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=akus_LonzaSublicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

License Agreement (Details)	1 Months Ended	3 Months Ended		9 Months Ended
License Agreement (Details)	Oct. 31, 2017 USD ($) item	Sep. 30, 2020 USD ($)	Sep. 30, 2019 USD ($)	Sep. 30, 2020 USD ($)	Sep. 30, 2019 USD ($)
License Agreements
Research and development		$ 8,641,000	$ 4,377,000	$ 26,612,000	$ 11,886,000
MEE License
License Agreements
Number of domestic patients \| item	3,000
IND filing period	18 months
Fair value of stock	$ 100,000
Milestone payment amount		0	0	0	0
Period for start commercial sale of product	10 years
Number of days for advance written notice	90 days
Research and development		0	0	0	0
MEE License \| Maximum
License Agreements
Milestone payment amount	$ 17,700,000
Lonza Sublicense
License Agreements
Number of domestic patients \| item	3,000
IND filing period	18 months
Fair value of stock	$ 100,000
Milestone payment amount		0	0	0	0
Period for start commercial sale of product	10 years
Number of days for advance written notice	90 days
Research and development		$ 0	$ 0	$ 0	$ 0
Lonza Sublicense \| Maximum
License Agreements
Milestone payment amount	$ 18,500,000